Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

MSD Completes Acquisition of Harpoon Therapeutics for ~USD$650M

Mar 11, 2024

On 11 March 2024, MSD announced the completion of the acquisition of Harpoon Therapeutics for about USD $650M with the aim of augmenting and diversifying their oncology pipeline.  Harpoon’s lead candidate is MK-6070 and its safety, tolerability and pharmacokinetics profile is currently being evaluated in a Phase 1/2 clinical trial (NCT04471727) in patients with advanced cancers.